160 related articles for article (PubMed ID: 7173449)
21. Use of adult fibroblasts coupled to muramyl dipeptide to induce antitumor immunity.
Eggers AE
J Biol Response Mod; 1988 Jun; 7(3):229-33. PubMed ID: 3392551
[TBL] [Abstract][Full Text] [Related]
22. Combined effects of synthetic lipid A analogs and muramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
Shimizu T; Ohtsuka Y; Yanagihara Y; Itoh H; Nakamoto S; Achiwa K
Int J Immunopharmacol; 1991; 13(5):605-11. PubMed ID: 1783474
[TBL] [Abstract][Full Text] [Related]
23. Use of Vaccinia virus as an adjuvant in inducing specific anti-tumour immunity to transplantable mouse fibrosarcoma. II. Rejection of tumour graft 'in vivo' humoral and lymphocytotoxicity 'in vitro'.
Bendre AR; Gangal SG
Indian J Cancer; 1978 Dec; 15(4):9-16. PubMed ID: 757692
[No Abstract] [Full Text] [Related]
24. N-[trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue.
Kikelj D; Pecar S; Kotnik V; Stalc A; Wraber-Herzog B; Simcic S; Ihan A; Klamfer L; Povsic L; Grahek R; Suhadolc E; Hocevar M; Hönig H; Rogi-Kohlenprath R
J Med Chem; 1998 Feb; 41(4):530-9. PubMed ID: 9484503
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of the local inflammatory response to bacterial infection by muramyl dipeptide.
Lamont PM; Schrodt GR; Galland RB; Kaufman CM; Cheadle WG; Polk HC
Br J Exp Pathol; 1984 Jun; 65(3):319-25. PubMed ID: 6743532
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic activity of the delta-endotoxin of Bacillus thuringiensis var thuringiensis (Berliner) on fibrosarcoma in Swiss mice.
Rao AS; Amonkar SV; Phondke GP
Indian J Exp Biol; 1979 Nov; 17(11):1208-12. PubMed ID: 549845
[No Abstract] [Full Text] [Related]
27. Effect of lysolecithin and analogs on mouse ascites tumors.
Tarnowski GS; Mountain IM; Stock CC; Munder PG; Weltzien HU; Westphal O
Cancer Res; 1978 Feb; 38(2):339-44. PubMed ID: 620405
[No Abstract] [Full Text] [Related]
28. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
29. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
[TBL] [Abstract][Full Text] [Related]
30. Analysis of synergy between cyclophosphamide therapy and immunity against a mouse tumour.
Chassoux DM; Gotch FM; MacLennan IC
Br J Cancer; 1978 Aug; 38(2):211-8. PubMed ID: 698035
[TBL] [Abstract][Full Text] [Related]
31. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
32. Use of Vaccinia virus as an adjuvant in inducing specific anti-tumour immunity to transplantable mouse fibrosarcoma. I. Adaptation of the virus to mouse tumour cells as a pre-requisit for adjuvanticity.
Bendre AR; Gangal SG
Indian J Cancer; 1978 Dec; 15(4):1-8. PubMed ID: 757683
[No Abstract] [Full Text] [Related]
33. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
Sarkar K; Das PK
J Immunol; 1997 Jun; 158(11):5357-65. PubMed ID: 9164956
[TBL] [Abstract][Full Text] [Related]
34. Relationship of anti-tuberculous protection to lung granuloma produced by intravenous injection of synthetic 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with or without specific antigens.
Yamamoto K; Kakinuma M; Kato K; Okuyama H; Azuma I
Immunology; 1980 Aug; 40(4):557-64. PubMed ID: 7000685
[TBL] [Abstract][Full Text] [Related]
35. Effect of dietary amino acids on tumour growth and cell-mediated immune responses.
Bounous G; Sadarangani C; Pang KC; Kongshavn PA
Clin Invest Med; 1981; 4(2):109-15. PubMed ID: 7026098
[No Abstract] [Full Text] [Related]
36. Radiation-induced changes in established tumor immunity.
Vaage J; Doroshow JH; DuBois TT
Cancer Res; 1974 Jan; 34(1):129-37. PubMed ID: 4809453
[No Abstract] [Full Text] [Related]
37. Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
Vondrys P; Símová J; Takácová S; Jandlová T; Bubeník J
Folia Biol (Praha); 1997; 43(1):39-40. PubMed ID: 9158948
[TBL] [Abstract][Full Text] [Related]
38. Radiocurability of a transplantable murine sarcoma as influenced by immune competence of the host and adjuvant active specific immunotherapy.
Deneufbourg JM
Strahlentherapie; 1975 Apr; 149(4):457-62. PubMed ID: 237344
[TBL] [Abstract][Full Text] [Related]
39. Toxicity to tumour cells of diethylaminoreserpine.
Lehnert S
Br J Cancer Suppl; 1980 Apr; 4():222-5. PubMed ID: 6932928
[TBL] [Abstract][Full Text] [Related]
40. Lectin potentiation of BCG-contact-mediated antitumor action.
Poduval TB; Seshadri M; Sundaram K
J Natl Cancer Inst; 1980 Nov; 65(5):909-12. PubMed ID: 6933260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
